Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions.

Researchers found that patients with obesity had an average weight loss of 12.9% with semaglutide vs 5.6% with liraglutide ...

Three doctors have expressed concerns to Newsweek about weight loss drugs for children, with research suggesting an initial reluctance to prescribe them.

China has started cracking down on unlicensed production and sale of medicines similar to Novo Nordisk A/S’s blockbuster ...

It’s a question that some users of semaglutide and tirzepatide injections, sold as Wegovy and Zepbound for weight loss, have ...

In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...

Whether positive or negative, your mood may feel different on GLP-1 medications. Researchers share why that might be and how ...

Meaning, whether you lose weight through a change in your diet, a different medication, or bariatric surgery, there is a risk ...

Management Services Organization (MSO) IntraCare and intermittent fasting app MogulBody have joined forces to create MogulBodyCare, LLC. The new company takes a multidirectional approach to weight ...

Three scientists were recognized by the Lasker Awards for their work on the GLP-1 hormone. Others were honored for work to ...

Three scientists are honored for developing a class of blockbuster weight-loss drugs. Is a Nobel prize on the way?